drugset / Trial / NCT05442580
CART-38 in Adult AML and MM Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".
Timeline
- Start
- 2023-05-30
- Primary completion
- 2025-02-09
- Completion
- 2025-02-09
Outcome
Outcome not reported
Stopped: “Administrative decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-38 cells | Cell therapy | 700000 cells | Intravenous |
| Subject | CART-38 cells | Cell therapy | 3e+06 cells | Intravenous |
| Subject | CART-38 cells | Cell therapy | 7e+06 cells | Intravenous |
| Subject | CART-38 cells | Cell therapy | 3e+07 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |